MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
48.40
+2.01 (4.33%)
Jun 24, 2026, 4:00 PM EDT - Market closed
MBX Biosciences Employees
MBX Biosciences had 63 employees as of December 31, 2025. The number of employees increased by 20 or 46.51% compared to the previous year.
Employees
63
Change (1Y)
20
Growth (1Y)
46.51%
Revenue / Employee
n/a
Profits / Employee
-$1,374,730
Market Cap
2.30B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 63 | 20 | 46.51% |
| Dec 31, 2024 | 43 | 16 | 59.26% |
| Sep 30, 2024 | 38 | 11 | 40.74% |
| Jun 30, 2024 | 36 | - | - |
| Mar 31, 2024 | 28 | - | - |
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| ADMA Biologics | 647 |
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 307 |
| Kardigan | 241 |
MBX News
- 12 days ago - MBX Biosciences down 19% at $30.05 after announcing canvuparatide study results - TheFly
- 12 days ago - MBX Biosciences Transcript: Study result - Transcripts
- 12 days ago - MBX Biosciences Slides: Study result - Filings
- 12 days ago - MBX Biosciences Press release: Study result - Filings
- 12 days ago - MBX Biosciences announces results from Avail, canvuparatide trials - TheFly
- 12 days ago - MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism - GlobeNewsWire
- 20 days ago - MBX Biosciences Transcript: AGM 2026 - Transcripts
- 21 days ago - MBX Biosciences Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts